Search Results
Sep 24, 2025, 06:00 ET ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
described in greater detail below), plus one CVR per Common Share, which CVR now represents the right to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the Transaction. The potential CVR payments of US$0.14
More news about: ESSA Pharma Inc.
Sep 22, 2025, 08:46 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRY, SCPH, WKHS on Behalf of Shareholders
$5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash. If you are a scPharmaceuticals shareholder,
More news about: Halper Sadeh LLP
Sep 16, 2025, 11:40 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHCO, VRNT, SCPH on Behalf of Shareholders
$5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash. If you are a scPharmaceuticals shareholder,
More news about: Halper Sadeh LLP
Sep 11, 2025, 08:35 ET Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
DURECT that were not tendered in the tender offer were converted into the right to receive $1.75 per share in cash plus one CVR. Following the closing of the tender offer and Merger, DURECT Corporation became a wholly owned subsidiary of Bausch Health. Prior to the opening
More news about: DURECT Corporation
Aug 28, 2025, 11:23 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWE, BKH, MURA, SCPH on Behalf of Shareholders
$5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash. If you are a scPharmaceuticals shareholder,
More news about: Halper Sadeh LLP
Aug 25, 2025, 11:54 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCPH, VTLE, CRGY on Behalf of Shareholders
$5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash. If you are a scPharmaceuticals shareholder,
More news about: Halper Sadeh LLP
Aug 22, 2025, 09:00 ET Diagnóstico precoce e tratamento adequado podem evitar 1,6 milhão de mortes por doença renal crônica e reduzir pela metade a necessidade de diálise no Brasil1
Medicine Working Group of the European Renal Association. Cardiovasc Res. 2023 Sep 5;119(11):2017-2032. doi: 10.1093/cvr/cvad083. PMID: 37249051; PMCID: PMC10478756.James G., et al. Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice
More news about: AstraZeneca
Aug 21, 2025, 08:30 ET ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment
cash balance and the net present value of the Takeda partnership for elritercept, which we believe the Company should distribute to stockholders via CVR. Given the large and persistent undervaluation of the Company's stock, we would like to work collaboratively with the Board to unlock this value for
More news about: ADAR1 Capital Management, LLC
Aug 18, 2025, 12:58 ET CHICAGO RIVET & MACHINE CO. DECLARES DIVIDEND
Ill., Aug. 18, 2025 /PRNewswire/ -- Chicago Rivet & Machine Co. (NYSE American: CVR) today announced that its Board of Directors declared a quarterly cash dividend of $0.03 per share payable September
More news about: Chicago Rivet & Machine Co.
Aug 08, 2025, 16:30 ET Chicago Rivet & Machine Co. Announces Second Quarter Results of Operations
Ill., Aug. 8, 2025 /PRNewswire/ -- Chicago Rivet & Machine Co. (NYSE American: CVR) today announced results for the second quarter of 2025 as summarized below:
More news about: Chicago Rivet & Machine Co.
Aug 06, 2025, 06:59 ET Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
$ 10,468 CVR liability
More news about: Q32 Bio
Aug 04, 2025, 11:37 ET Shareholder Alert: The Ademi Firm investigates whether HilleVax, Inc. is obtaining a Fair Price for its Public Shareholders
In the transaction, shareholders of HilleVax will receive $1.95 per share in cash plus contingent value rights. The CVR provides potential additional payments based on HilleVax's remaining cash above $102.95 million, savings from Boston
More news about: Ademi LLP
Aug 04, 2025, 08:00 ET Icahn Enterprises L.P. (Nasdaq: IEP) Today Announced Its Second Quarter 2025 Financial Results
$ 2,703 CVR Energy(2) 1,891
More news about: Icahn Enterprises L.P.
Jul 24, 2025, 08:00 ET Lilly and Verve announce expiration of Verve tender offer
applicable tax withholding, plus (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding,
More news about: Eli Lilly and Company
Jul 23, 2025, 13:01 ET Shay Capital Letter to the Board of Beyond Inc.
Medici on the balance sheet. Issue a Contingent Value Right (CVR): Distribute a CVR to all Beyond shareholders, tied to the monetization of the Medici Ventures portfolio (excluding tZero and GrainChain). This CVR, to be traded on the NYSE under the ticker "BYONR," will provide immediate
More news about: Shay Capital LLC
Jul 18, 2025, 17:32 ET $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: VRNA, BPMC, DALN, and RGLD
shareholders also will receive one non-tradeable contingent value right ("CVR") entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achievement, respectively, of future development and regulatory
More news about: Monteverde & Associates PC
Jul 14, 2025, 08:00 ET ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction
receive one non-transferable contingent value right (each, a "CVR") for each Common Share that entitles the holder to receive a pro rata portion of up to US$2,950,000 (up to US$0.06 per CVR) within 18 months following the close of the Transaction.
More news about: ESSA Pharma Inc
Jul 14, 2025, 07:30 ET Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions
of approximately $168 million. Monogram common stockholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development, regulatory
More news about: Zimmer Biomet Holdings, Inc.
Jul 03, 2025, 17:34 ET $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: TASK, VIGL, STRM, and CHTR
following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis.ACT NOW. The Shareholder Vote
More news about: Monteverde & Associates PC
Jun 23, 2025, 13:30 ET SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SAGE, SOL on Behalf of Shareholders
shareholders also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achievement, respectively, of future development and regulatory
More news about: Halper Sadeh LLP
Jun 17, 2025, 06:45 ET Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
$1.3 billion). CVR holders would become entitled to receive the contingent payment upon the first patient being dosed with VERVE-102 for ASCVD in a U.S. Phase 3 clinical trial on or prior to the tenth anniversary of closing or termination of the CVR. There can be no assurance that any
More news about: Eli Lilly and Company
Jun 09, 2025, 08:00 ET Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right
$0.36 in cash per share of Elevation Oncology common stock ("Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of
More news about: Elevation Oncology